抗肝纤方对早期肝硬化门脉高压症患者血流动力学的影响

Influence of anti-hepato-fibrosis prescription on hemodynamics in patients with early-stage liver cirrhosis complicated with portal hypertension

目的：探讨抗肝纤方对早期肝硬化门脉高压症患者血流动力学的影响。方法2013年1月~2014年5月，将符合诊断标准的60例患者，按照随机数字表法分为治疗组和对照组各30例，治疗组采用抗纤方治疗，对照组使用盐酸普萘洛尔配合大黄蟅虫胶囊进行治疗。观察两组治疗前后的门静脉内径（DPV）、脾静脉内径（DSV）、脾静脉血流量（SVF）、门静脉血流量（PVF）及肝纤维化指标变化情况。结果治疗后，两组均能明显降低血清中HA、PCⅢ、LN、CⅣ值，但两组差异无统计学意义（P〉0.05）；两组均能降低DPV、DSV、PVF值，且治疗组的SVF值明显降低（P〈0.01），治疗后，两组患者的DSV、PVF、SVF值比较，差异有统计学意义（P〈0.05）。结论抗肝纤方能有效地缓解患者的肝纤维化病情，且可改善其血流动力学指标，值得在临床推广。

Objective To explore the influence of anti-hepato-fibrosis prescription on hemodynamics in patients with early-stage liver cirrhosis and portal hypertension. Methods From January 2013 to May 2014,sixty patients meeting the diagnostic criteria were evenly divided into treatment group and control group by random number table.In the treatment group,anti-hepato-fibrosis prescription was used,while in the control group,propranolole hydrochloride combining with Dahuang Zhechong Capsule was adopted.Change of indexes including diameter of portal vein （DPV）,diameter of splenic vein （DSV）,spleen venous flow （SVF）,portal venous flow （PVF）,and hepatic fibrosis before and after treatment were ob-served. Results After treatment,value of HA,PCⅢ,LN,and CⅣ in serum were decreased in both groups,but didn’t dis-play significant difference between two groups.Value of DPV,DSV,and PVF in the two groups were decreased,and value of SVF in the treatment group was significantly decreased （P〈0.01）.There were statistical differences in values of DSV, PVF,and SVF between two groups after therapy （P〈0.05）. Conclusion Anti-hepato-fibrosis prescription can effectively alleviate hepatic fibrosis,and also improve hemodynamics in patients with early-stage liver cirrhosis and portal hyper-tension,which is worthy of clinical promotion.